Reviews and Expert Analysis · industry-kpi

What are the key sales KPIs for the Medical Device OEM industry in 2027?

👁 0 views📖 2,027 words⏱ 9 min read5/30/2026

Direct Answer

The nine KPIs that actually run a medical device OEM in 2027 are: Instrument/Capital Placement Count (units placed), Recurring-Consumable Revenue Mix % (razor-and-blade), Surgeon Adoption Rate (% of target surgeons trained + active), GPO Contract Win Rate %, Hospital VAC Approval Rate %, Capital-vs-Recurring Revenue Split, Robotics Adoption Rate (% of target procedures done robotically), Product-Launch Ramp Rate ($ revenue per quarter post-launch), and Average Selling Price (ASP) Erosion % YoY.

A tenth, Regional Revenue Mix (US / EMEA / APAC / Emerging Markets), sits next to them as the geographic-exposure metric. Together they answer the only three questions a med-device CFO actually cares about: are we placing capital, are the placed systems generating consumables, and is the surgeon community pulling the next product forward.

TL;DR
— Capital placements feed recurring consumables, consumables fund the next R&D cycle, and the next-gen platform pulls more capital placements — that is the loop. A healthy device OEM runs 60-75% recurring revenue mix, surgeon adoption above 70% in target accounts, and ASP erosion under 3% per year.
Track the nine KPIs weekly, refresh the GPO and VAC pipeline monthly, and re-baseline the robotics-adoption ramp quarterly — that is the operating cadence Medtronic, Stryker, Boston Scientific, Abbott, and Intuitive Surgical all converged on after the 2024-2026 hospital capital squeeze.

Why Medical Device OEMs Work Differently

Med-device is not pharma, even though both sit inside healthcare. Four mechanics make it its own category.

Razor-and-blade economics. A surgical platform — a da Vinci system, a Mako robot, a Hugo, a stapler driver, an electrophysiology mapping console — is sold or placed at relatively thin margin. The real economics sit in the recurring consumables: instruments, accessories, single-use cartridges, energy devices, and service contracts.

Intuitive Surgical reported Q1 2026 instruments-and-accessories revenue of $1.69B against systems revenue of ~$523M — recurring is now ~76% of total. The CFO question is not "how many systems did you sell" — it is "how many procedures per system per quarter, and what's the consumable pull-through."

Hospital VAC approval is the real gate. Hospitals do not buy on a sales call. A new product enters a Value Analysis Committee — a multi-disciplinary review of clinical evidence, cost, and operational fit — and 6-12 months later either gets approved, rejected, or sent back for more data.

ECRI and AHA Procurement Council benchmarks show median VAC cycle time of ~9 months. Sales-cycle math in med-device looks like enterprise SaaS without the self-serve safety valve.

GPO contracts gate access at scale. Group Purchasing Organizations (Vizient, Premier, HealthTrust) negotiate master pricing on behalf of ~95% of US acute-care hospitals. A device without a tier-1 GPO contract starts every account with a 5-15% pricing handicap before the rep walks in.

GPO contract wins are the single biggest delta on a quarterly revenue forecast.

Surgeon-pull beats hospital-push. A device OEM cannot force a hospital to switch platforms — the surgeon does, by requesting privileges, training, and case scheduling. Intuitive Surgical's da Vinci installed base of ~11,395 systems as of Q1 2026 was built one surgeon at a time, over 25 years.

Stryker's Mako crossed 2 million procedures in 2025 because two-thirds of US knee replacements at Mako accounts now use the robot. Surgeon adoption rate is the leading indicator that predicts procedure volume 2-3 quarters out.

The 9 KPIs, In Depth

1. Instrument/Capital Placement Count (units placed). Systems placed per quarter, split between sale, lease, and usage-based agreements. Intuitive placed 431 da Vinci systems in Q1 2026 (232 were da Vinci 5); Stryker reports Mako installed base as ~3,000+ globally; Medtronic's Hugo crossed FDA clearance in early 2026 with first US cases.

Track gross placements AND trade-ins (the next-gen platform usually displaces the older one inside the same account).

2. Recurring-Consumable Revenue Mix % (razor-and-blade). Instruments, accessories, single-use disposables, and service as a share of total revenue. Best-in-class: Intuitive at ~85% recurring; Edwards Lifesciences (TAVR) at ~90%; Stryker MedSurg blended at ~55%. Higher recurring mix is what drives the 30x+ revenue multiple Intuitive trades at.

3. Surgeon Adoption Rate (% of target surgeons trained + active). Share of target-account surgeons who have completed training AND performed cases in the last 90 days. Trained-but-inactive surgeons are a leading indicator of churn — they will lose privileges or default back to the competitor's platform.

Veeva CRM's medical-account module is the system of record for most majors.

4. GPO Contract Win Rate %. Share of head-to-head GPO RFPs won in the last 12 months. Best-in-class is 50%+ across the four major GPOs (Vizient, Premier, HealthTrust, Intalere). Tracked separately because losing a single Vizient master contract can cost $200M+ in run-rate revenue.

5. Hospital VAC Approval Rate %. Share of submitted VAC packets that get approved on first or second submission. Best-in-class is 60%+ first-pass approval with median cycle time under 9 months. Tracked because the inverse — a failed VAC — locks the OEM out of that account for 12-24 months before resubmission.

6. Capital-vs-Recurring Revenue Split. Capital sales (systems, instruments at placement) vs. Recurring (consumables, service, leases). Pure-capital OEMs trade at 3-5x revenue; high-recurring-mix OEMs trade at 10-15x+. This is the single biggest valuation driver in med-device public comps.

7. Robotics Adoption Rate (% of target procedures done robotically). Share of in-scope procedures performed using a robotic platform. Intuitive's da Vinci procedure growth was ~16% in Q1 2026; Ion (lung biopsy) grew ~39%; Stryker reports Mako used in 66%+ of US knee and 33% of US hip cases at Mako accounts.

Tracked because robotic procedures pull 4-8x the consumable revenue of an equivalent open procedure.

8. Product-Launch Ramp Rate ($ revenue per quarter post-launch). Quarterly revenue trajectory in the first 8 quarters after launch, compared to internal forecast and analog launches. Inari Medical's thrombectomy ramp, Edwards' Sapien 4 TAVR ramp, and Boston Scientific's Watchman are the canonical case studies.

Slope matters more than absolute number — a flat ramp predicts a missed peak forecast.

9. ASP Erosion % YoY. Year-over-year change in average selling price within a defined product family. Mature device categories (orthopedic implants, drug-eluting stents, pacemakers) run 2-5% annual ASP erosion; new categories (TAVR, structural heart, PFA ablation) can hold or even grow ASP for 5-7 years.

Tracked at the SKU level so mix shifts do not mask underlying price compression.

flowchart TD A[Capital System Placement] --> B[Surgeon Training Program] B --> C{Surgeon Adoption over 70 percent at account} C -->|Yes| D[Active Case Volume] C -->|No| E[Stranded Capital - System Idle] D --> F[Consumable Pull-Through per Procedure] F --> G[Recurring Revenue 60-85 percent of mix] G --> H{ASP Erosion under 3 percent YoY} H -->|Yes| I[Healthy Unit Economics] H -->|No| J[Margin Compression] I --> K[R&D Funded for Next Platform] K --> L[Next-Gen Robotics or Energy Platform] L --> M[VAC Approval and GPO Contract Win] M --> A E --> N[Retraining or System Pull-Back]

Real Operators

Medtronic is the broadest med-device portfolio — cardiac, neuromodulation, diabetes, structural heart, surgical, with the Hugo robotics platform now FDA-cleared and ramping. Stryker runs the orthopedic and MedSurg play — Mako robot at 3,000+ installations, the new Mako RPS handheld knee robot in limited release, and the highest organic growth rate of the big-three orthos.

Boston Scientific owns electrophysiology with the Farapulse PFA platform plus structural heart with Watchman. Abbott runs the most diversified portfolio — Libre CGM, MitraClip, Navitor TAVR, plus diagnostics. Edwards Lifesciences is the TAVR pure-play with Sapien 3 Ultra and Sapien 4, plus Pascal mitral.

Intuitive Surgical is the canonical razor-and-blade story — 11,395+ da Vinci installed base, 76% recurring revenue mix, Ion bronchoscopy ramping at 39% Q1 2026 growth. Becton Dickinson runs the hospital-essentials franchise (needles, IV sets, lab automation) at scale. Zimmer Biomet competes in orthopedics with the Rosa robotics platform.

Hologic owns women's health diagnostics — 3D Mammography, ThinPrep, Aptima. Johnson & Johnson MedTech rounds out the top tier with the Ottava robot under development and the Velys orthopedic platform.

Failure Modes

The four that kill device OEM launches. (1) Capital placement without consumable pull-through — systems land in hospitals, get used for 3 cases, and sit idle; the recurring revenue thesis collapses. (2) GPO contract loss without a backup channel — losing the Vizient master contract and trying to sell account-by-account turns a 90-day cycle into a 12-month one.

(3) VAC packet weakness — submitting clinical evidence that does not address the cost-of-care question the committee actually asks; the packet bounces and burns 9 months. (4) Robotics over-investment without procedure economics — building the next-gen robot and forgetting that the hospital P&L needs the per-procedure cost to come down, not up.

Reporting Cadence

Daily: capital orders booked, system installations completed, surgeon training sessions held. Weekly: consumable revenue by account, surgeon adoption rate by region, VAC pipeline status, GPO RFP movement. Monthly: capital-vs-recurring split, ASP erosion by product family, robotics adoption rate vs.

Target, launch ramp vs. Forecast. Quarterly: full P&L by franchise, GPO contract renewal calendar refresh, regional mix recalc, and the long-range R&D pipeline review tied to next-platform launch timing.

flowchart TD A[Daily Veeva CRM + ERP] --> B[Capital Orders + Installs + Training] B --> C[Weekly Operating Review] C --> D[Consumable Revenue + Surgeon Adoption + VAC + GPO Pipeline] D --> E[Monthly Franchise Business Review] E --> F[Capital vs Recurring Split + ASP Erosion + Robotics Adoption] F --> G[Quarterly Franchise P&L + Board] G --> H[GPO Renewal Calendar + Regional Mix + R&D Pipeline] H --> I[Re-forecast Placement + Pull-Through + Launch Ramp] I --> A

30/60/90 Day Plan

Days 1–30: instrument the nine KPIs end-to-end. Reconcile capital placement counts in Salesforce/Veeva against the revenue recognized in the GL — sale, lease, and usage-based placements get recognized differently and the three views will not match on day one. Baseline surgeon adoption rate by account and identify the top-decile under-utilization accounts.

Days 31–60: ship the recurring-revenue and ASP-erosion dashboard. Wire it to the consumable shipment data on one side and the GPO contract pricing schedules on the other. Build the VAC pipeline tracker with cycle-time analytics so committee bottlenecks become visible.

Identify the three accounts with the highest stranded-capital risk and brief field clinical specialists.

Days 61–90: rebuild the robotics-adoption forecast for the next 8 quarters by account tier. Refresh the GPO contract calendar with renewal dates and bid-defense plans. Run the next-platform launch readiness scorecard against any product within 12 months of FDA clearance.

Present the new operating model to the CFO and CCO with monthly KPI checkpoints and quarterly franchise-level board cuts.

FAQ

Why is recurring revenue mix the most-watched valuation metric in med-device? Because the multiple expansion is real. A pure-capital OEM trades at 3-5x revenue; a high-recurring OEM (Intuitive, Edwards, Inspire Medical) trades at 10-15x+. The market pays for predictable per-procedure revenue from a stranded capital base.

How long is a typical hospital VAC approval cycle? Median ~9 months from first packet submission to approved purchase order, per ECRI benchmarks. Larger IDNs (HCA, Ascension, CommonSpirit) run longer (12-18 months) because the packet has to pass system-level review on top of facility-level. Plan launches accordingly.

What is the right ratio of capital reps to clinical specialists? Roughly 1:2 capital-to-clinical for a robotics or capital-heavy platform (one capital sales rep per two procedural clinical specialists), inverting to 2:1 for a consumables-heavy franchise where the clinical specialist drives the consumable pull.

Stryker and Intuitive both publish field-coverage models that confirm this split.

How fast does ASP erode in mature device categories? 2-5% per year is the steady-state for mature implant categories (orthopedic knees, drug-eluting stents, dual-chamber pacemakers). New categories (TAVR, PFA, structural-heart) can hold or grow ASP for 5-7 years before competitive entry starts the erosion.

Track at SKU level — mix shifts can mask 8%+ underlying erosion in any single product family.

Sources

AdvaMed — Industry Outlook and State of the Medical Technology Industry Report
ECRI Institute — Value Analysis and Procurement Benchmarks
AAMI — Medical Device Quality and Adoption Standards
MedTech Strategist — Device Launch and Robotics Market Analysis
Vizient and Premier — GPO Contract and Hospital Spend Reports
Medtronic plc — Form 10-K (FY 2026)
Stryker Corporation — Form 10-K (FY 2025)
Boston Scientific Corporation — Form 10-K (FY 2025)
Abbott Laboratories — Form 10-K (FY 2025)
Edwards Lifesciences — Form 10-K (FY 2025)
Intuitive Surgical — Form 10-K and Q1 2026 Earnings Release
Becton Dickinson — Form 10-K (FY 2025)

Keep reading

Download:

### Direct Answer

The nine KPIs that actually run a medical device OEM in 2027 are: **Instrument/Capital Placement Count (units placed)**, **Recurring-Consumable Revenue Mix % (razor-and-blade)**, **Surgeon Adoption Rate (% of target surgeons trained + active)**, **GPO Contract Win Rate %**, **Hospital VAC Approval Rate %**, **Capital-vs-Recurring Revenue Split**, **Robotics Adoption Rate (% of target procedures done robotically)**, **Product-Launch Ramp Rate ($ revenue per quarter post-launch)**, and **Average Selling Price (ASP) Erosion % YoY**. A tenth, **Regional Revenue Mix (US / EMEA / APAC / Emerging Markets)**, sits next to them as the geographic-exposure metric. Together they answer the only three questions a med-device CFO actually cares about: are we placing capital, are the placed systems generating consumables, and is the surgeon community pulling the next product forward.

> **TL;DR** — Capital placements feed recurring consumables, consumables fund the next R&D cycle, and the next-gen platform pulls more capital placements — that is the loop. A healthy device OEM runs 60-75% recurring revenue mix, surgeon adoption above 70% in target accounts, and ASP erosion under 3% per year. Track the nine KPIs weekly, refresh the GPO and VAC pipeline monthly, and re-baseline the robotics-adoption ramp quarterly — that is the operating cadence Medtronic, Stryker, Boston Scientific, Abbott, and Intuitive Surgical all converged on after the 2024-2026 hospital capital squeeze.

## Why Medical Device OEMs Work Differently

Med-device is not pharma, even though both sit inside healthcare. Four mechanics make it its own category.

**Razor-and-blade economics.** A surgical platform — a da Vinci system, a Mako robot, a Hugo, a stapler driver, an electrophysiology mapping console — is sold or placed at relatively thin margin. The real economics sit in the recurring consumables: instruments, accessories, single-use cartridges, energy devices, and service contracts. Intuitive Surgical reported Q1 2026 instruments-and-accessories revenue of $1.69B against systems revenue of ~$523M — recurring is now ~76% of total. The CFO question is not "how many systems did you sell" — it is "how many procedures per system per quarter, and what's the consumable pull-through."

**Hospital VAC approval is the real gate.** Hospitals do not buy on a sales call. A new product enters a Value Analysis Committee — a multi-disciplinary review of clinical evidence, cost, and operational fit — and 6-12 months later either gets approved, rejected, or sent back for more data. ECRI and AHA Procurement Council benchmarks show median VAC cycle time of ~9 months. Sales-cycle math in med-device looks like enterprise SaaS without the self-serve safety valve.

**GPO contracts gate access at scale.** Group Purchasing Organizations (Vizient, Premier, HealthTrust) negotiate master pricing on behalf of ~95% of US acute-care hospitals. A device without a tier-1 GPO contract starts every account with a 5-15% pricing handicap before the rep walks in. GPO contract wins are the single biggest delta on a quarterly revenue forecast.

**Surgeon-pull beats hospital-push.** A device OEM cannot force a hospital to switch platforms — the surgeon does, by requesting privileges, training, and case scheduling. Intuitive Surgical's da Vinci installed base of ~11,395 systems as of Q1 2026 was built one surgeon at a time, over 25 years. Stryker's Mako crossed 2 million procedures in 2025 because two-thirds of US knee replacements at Mako accounts now use the robot. Surgeon adoption rate is the leading indicator that predicts procedure volume 2-3 quarters out.

## The 9 KPIs, In Depth

**1. Instrument/Capital Placement Count (units placed).** Systems placed per quarter, split between sale, lease, and usage-based agreements. Intuitive placed 431 da Vinci systems in Q1 2026 (232 were da Vinci 5); Stryker reports Mako installed base as ~3,000+ globally; Medtronic's Hugo crossed FDA clearance in early 2026 with first US cases. Track gross placements AND trade-ins (the next-gen platform usually displaces the older one inside the same account).

**2. Recurring-Consumable Revenue Mix % (razor-and-blade).** Instruments, accessories, single-use disposables, and service as a share of total revenue. Best-in-class: Intuitive at ~85% recurring; Edwards Lifesciences (TAVR) at ~90%; Stryker MedSurg blended at ~55%. Higher recurring mix is what drives the 30x+ revenue multiple Intuitive trades at.

**3. Surgeon Adoption Rate (% of target surgeons trained + active).** Share of target-account surgeons who have completed training AND performed cases in the last 90 days. Trained-but-inactive surgeons are a leading indicator of churn — they will lose privileges or default back to the competitor's platform. Veeva CRM's medical-account module is the system of record for most majors.

**4. GPO Contract Win Rate %.** Share of head-to-head GPO RFPs won in the last 12 months. Best-in-class is 50%+ across the four major GPOs (Vizient, Premier, HealthTrust, Intalere). Tracked separately because losing a single Vizient master contract can cost $200M+ in run-rate revenue.

**5. Hospital VAC Approval Rate %.** Share of submitted VAC packets that get approved on first or second submission. Best-in-class is 60%+ first-pass approval with median cycle time under 9 months. Tracked because the inverse — a failed VAC — locks the OEM out of that account for 12-24 months before resubmission.

**6. Capital-vs-Recurring Revenue Split.** Capital sales (systems, instruments at placement) vs. Recurring (consumables, service, leases). Pure-capital OEMs trade at 3-5x revenue; high-recurring-mix OEMs trade at 10-15x+. This is the single biggest valuation driver in med-device public comps.

**7. Robotics Adoption Rate (% of target procedures done robotically).** Share of in-scope procedures performed using a robotic platform. Intuitive's da Vinci procedure growth was ~16% in Q1 2026; Ion (lung biopsy) grew ~39%; Stryker reports Mako used in 66%+ of US knee and 33% of US hip cases at Mako accounts. Tracked because robotic procedures pull 4-8x the consumable revenue of an equivalent open procedure.

**8. Product-Launch Ramp Rate ($ revenue per quarter post-launch).** Quarterly revenue trajectory in the first 8 quarters after launch, compared to internal forecast and analog launches. Inari Medical's thrombectomy ramp, Edwards' Sapien 4 TAVR ramp, and Boston Scientific's Watchman are the canonical case studies. Slope matters more than absolute number — a flat ramp predicts a missed peak forecast.

**9. ASP Erosion % YoY.** Year-over-year change in average selling price within a defined product family. Mature device categories (orthopedic implants, drug-eluting stents, pacemakers) run 2-5% annual ASP erosion; new categories (TAVR, structural heart, PFA ablation) can hold or even grow ASP for 5-7 years. Tracked at the SKU level so mix shifts do not mask underlying price compression.

```mermaid
flowchart TD
    A[Capital System Placement] --> B[Surgeon Training Program]
    B --> C{Surgeon Adoption over 70 percent at account}
    C -->|Yes| D[Active Case Volume]
    C -->|No| E[Stranded Capital - System Idle]
    D --> F[Consumable Pull-Through per Procedure]
    F --> G[Recurring Revenue 60-85 percent of mix]
    G --> H{ASP Erosion under 3 percent YoY}
    H -->|Yes| I[Healthy Unit Economics]
    H -->|No| J[Margin Compression]
    I --> K[R&D Funded for Next Platform]
    K --> L[Next-Gen Robotics or Energy Platform]
    L --> M[VAC Approval and GPO Contract Win]
    M --> A
    E --> N[Retraining or System Pull-Back]
```

## Real Operators

**Medtronic** is the broadest med-device portfolio — cardiac, neuromodulation, diabetes, structural heart, surgical, with the Hugo robotics platform now FDA-cleared and ramping. **Stryker** runs the orthopedic and MedSurg play — Mako robot at 3,000+ installations, the new Mako RPS handheld knee robot in limited release, and the highest organic growth rate of the big-three orthos. **Boston Scientific** owns electrophysiology with the Farapulse PFA platform plus structural heart with Watchman. **Abbott** runs the most diversified portfolio — Libre CGM, MitraClip, Navitor TAVR, plus diagnostics. **Edwards Lifesciences** is the TAVR pure-play with Sapien 3 Ultra and Sapien 4, plus Pascal mitral. **Intuitive Surgical** is the canonical razor-and-blade story — 11,395+ da Vinci installed base, 76% recurring revenue mix, Ion bronchoscopy ramping at 39% Q1 2026 growth. **Becton Dickinson** runs the hospital-essentials franchise (needles, IV sets, lab automation) at scale. **Zimmer Biomet** competes in orthopedics with the Rosa robotics platform. **Hologic** owns women's health diagnostics — 3D Mammography, ThinPrep, Aptima. **Johnson & Johnson MedTech** rounds out the top tier with the Ottava robot under development and the Velys orthopedic platform.

## Failure Modes

The four that kill device OEM launches. **(1) Capital placement without consumable pull-through** — systems land in hospitals, get used for 3 cases, and sit idle; the recurring revenue thesis collapses. **(2) GPO contract loss without a backup channel** — losing the Vizient master contract and trying to sell account-by-account turns a 90-day cycle into a 12-month one. **(3) VAC packet weakness** — submitting clinical evidence that does not address the cost-of-care question the committee actually asks; the packet bounces and burns 9 months. **(4) Robotics over-investment without procedure economics** — building the next-gen robot and forgetting that the hospital P&L needs the per-procedure cost to come down, not up.

## Reporting Cadence

**Daily:** capital orders booked, system installations completed, surgeon training sessions held. **Weekly:** consumable revenue by account, surgeon adoption rate by region, VAC pipeline status, GPO RFP movement. **Monthly:** capital-vs-recurring split, ASP erosion by product family, robotics adoption rate vs. Target, launch ramp vs. Forecast. **Quarterly:** full P&L by franchise, GPO contract renewal calendar refresh, regional mix recalc, and the long-range R&D pipeline review tied to next-platform launch timing.

```mermaid
flowchart TD
    A[Daily Veeva CRM + ERP] --> B[Capital Orders + Installs + Training]
    B --> C[Weekly Operating Review]
    C --> D[Consumable Revenue + Surgeon Adoption + VAC + GPO Pipeline]
    D --> E[Monthly Franchise Business Review]
    E --> F[Capital vs Recurring Split + ASP Erosion + Robotics Adoption]
    F --> G[Quarterly Franchise P&L + Board]
    G --> H[GPO Renewal Calendar + Regional Mix + R&D Pipeline]
    H --> I[Re-forecast Placement + Pull-Through + Launch Ramp]
    I --> A
```

## 30/60/90 Day Plan

**Days 1–30:** instrument the nine KPIs end-to-end. Reconcile capital placement counts in Salesforce/Veeva against the revenue recognized in the GL — sale, lease, and usage-based placements get recognized differently and the three views will not match on day one. Baseline surgeon adoption rate by account and identify the top-decile under-utilization accounts.

**Days 31–60:** ship the recurring-revenue and ASP-erosion dashboard. Wire it to the consumable shipment data on one side and the GPO contract pricing schedules on the other. Build the VAC pipeline tracker with cycle-time analytics so committee bottlenecks become visible. Identify the three accounts with the highest stranded-capital risk and brief field clinical specialists.

**Days 61–90:** rebuild the robotics-adoption forecast for the next 8 quarters by account tier. Refresh the GPO contract calendar with renewal dates and bid-defense plans. Run the next-platform launch readiness scorecard against any product within 12 months of FDA clearance. Present the new operating model to the CFO and CCO with monthly KPI checkpoints and quarterly franchise-level board cuts.

## FAQ

**Why is recurring revenue mix the most-watched valuation metric in med-device?** Because the multiple expansion is real. A pure-capital OEM trades at 3-5x revenue; a high-recurring OEM (Intuitive, Edwards, Inspire Medical) trades at 10-15x+. The market pays for predictable per-procedure revenue from a stranded capital base.

**How long is a typical hospital VAC approval cycle?** Median ~9 months from first packet submission to approved purchase order, per ECRI benchmarks. Larger IDNs (HCA, Ascension, CommonSpirit) run longer (12-18 months) because the packet has to pass system-level review on top of facility-level. Plan launches accordingly.

**What is the right ratio of capital reps to clinical specialists?** Roughly 1:2 capital-to-clinical for a robotics or capital-heavy platform (one capital sales rep per two procedural clinical specialists), inverting to 2:1 for a consumables-heavy franchise where the clinical specialist drives the consumable pull. Stryker and Intuitive both publish field-coverage models that confirm this split.

**How fast does ASP erode in mature device categories?** 2-5% per year is the steady-state for mature implant categories (orthopedic knees, drug-eluting stents, dual-chamber pacemakers). New categories (TAVR, PFA, structural-heart) can hold or grow ASP for 5-7 years before competitive entry starts the erosion. Track at SKU level — mix shifts can mask 8%+ underlying erosion in any single product family.

## Sources

- AdvaMed — Industry Outlook and State of the Medical Technology Industry Report
- ECRI Institute — Value Analysis and Procurement Benchmarks
- AAMI — Medical Device Quality and Adoption Standards
- MedTech Strategist — Device Launch and Robotics Market Analysis
- Vizient and Premier — GPO Contract and Hospital Spend Reports
- Medtronic plc — Form 10-K (FY 2026)
- Stryker Corporation — Form 10-K (FY 2025)
- Boston Scientific Corporation — Form 10-K (FY 2025)
- Abbott Laboratories — Form 10-K (FY 2025)
- Edwards Lifesciences — Form 10-K (FY 2025)
- Intuitive Surgical — Form 10-K and Q1 2026 Earnings Release
- Becton Dickinson — Form 10-K (FY 2025)

Was this helpful?

Related in the library